ASML reports €8.8 billion total net sales and €2.8 billion net income in Q1 2026 ASML now expects 2026 total net sales to be between €36 billion and €40 billion, with a gross margin between 51% and 53% ASML 2026 first-quarter results Veldhoven, the Netherlands April 15, 2026 Agenda April 15, 2026 Page 2 Public • Investor key messages • Business summary • Outlook • Financial statements Investor key messages April 15, 2026 Page 3 Investor key messages1 April 15, 2026 Page 4 1 Investor key messages as presente ...

1Q26 Financial Results April 14, 2026 © 2026 Wells Fargo Bank, N.A. All rights reserved. Improved financial results driven by momentum across businesses • Earnings per diluted share of $1.60, up 15% Consumer Banking and Lending Wealth and Investment Management Comparisons in the bullet points are for 1Q26 versus 1Q25, unless otherwise noted. Operating leverage means the percentage change in revenue minus the percentage change in noninterest expense. Endnotes are presented starting on page 22. 1Q26 Financial ...

April 14, 2026 1Q26 Financial Results 1Q26 Financial highlights | | CET1 capital ratios2 | $2.0T Std. RWA3 | | --- | --- | --- | | ROTCE1 | 14.3% Adv. 14.1% Std. | $1.5T Cash and marketable securities4 | | 23% | $572B Total Loss-Absorbing Capacity2 | $1.5T Average loans | 4 Cash and marketable securities represent HQLA and unencumbered marketable securities. Estimated for the current period. See note 1 on slide 11 5 See note 1 on slide 10 | 1Q26 net income of $16.5B and EPS of $5.94 |  | Managed revenue of ...

st April 14, 2026 3 Strategic partnerships, collaborations & licensing arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration wit ...

Fourth Quarter FY2026 Financial Results Jorik Ittmann, President and CEO Tom DeByle, Chief Financial Officer 2 Fiscal 2026: A Foundational Reset Year Printing Technologies for Critical Applications April 13, 2026 Nasdaq: ALOT AstroNova Cautionary Statement Information included in this presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact but rather reflect our current ex ...

Investor Fourth Quarter 2025 Presentation Disclaimer Certain matters discussed in this presentation contain forward-looking statements concerning our business, operations and financial performance and conditions, as well as our plans, objectives and expectations for our business operations and financial performance and condition. These statements may be preceded by, followed by or include the words "may," "expect," "will," "will likely result," "should," "estimate," "plan" and other similar expressions that ...

F Y 2 0 2 5 E A R N I N GS P R E S E N TAT I ON A P R I L 2 0 2 6 Disclaimer Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes certain financial measures that have not been prepared in a manner that complies with generally accepted accounting principles in the United States ("GAAP"), including, without limitation, Adjusted EBITDA, EBITDA per Indenture, same station revenue, same station operating expenses, EBITDA, and Station Operating Income ("SOI" and "SOI Margin") (col ...

LIXIL IMPACT BRIEFING: April 3, 2026 Empowering Change: Scaling Impact in a New Era Copyright © LIXIL Corporation. All rights reserved. Today's Speakers Kinya Seto Director, Representative Executive Officer, President, and Chief Executive Officer Erin McCusker Executive Officer, Executive Vice President, Chief Impact Officer, Communications, External Affairs, and Impact Strategy 1 Outside Director, Chairperson of the Board of Directors and Chairperson of Governance Committee Ryusuke Ohori ––––– Outside Dire ...

R&D Day 2026 April 2, 2026 Bettering the Lives of People Impacted by Kidney Disease NASDAQ: AKBA 1 Cautionary note on forward-looking statements Statements in this presentation regarding Akebia Therapeutics, Inc.'s ("Akebia's") strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are not limited to, statements regarding: Akebia's plans, strategies an ...

FISCAL 2026 SECOND-QUARTER RESULTS APRIL 2, 2026 BMS Software Suite Mark Architectural Lighting , Juno®, Gotham ® Lighting: CIBC Square, Toronto FORWARD LOOKING STATEMENTS This presentation and related conference call and webcast contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (the ...